



The British Society for
Antimicrobial Chemotherapy



OPAT
Outpatient Parenteral
Antimicrobial Therapy

Intravenous Antibiotics in Homecare – The Bupa Experience

Stephen Cook





INTRAVENOUS ANTIBIOTICS IN HOMECARE

The Bupa Experience

Stephen Cook, Director of Pharmacy
6th June 2013

Agenda

1. Introduction to Bupa and Bupa Home Healthcare
2. Out of Hospital Care
3. The OPAT Experience
4. Questions & Discussion

We are Bupa

Helping people live longer, healthier, happier lives

In the UK

- Almost 300 care homes look after over 17,900 residents
- A leading hospital in London with 128 beds treats over 10,000 people a year
- 13,000 drug deliveries to patients each month from 3 aseptic compounding units
- We insure over 2.7m lives
- 32,216 people make up Bupa UK

Bupa around the world


- A global player
- Over 60 years
- 11.8 million customers
- Over 190 countries
- 29,000 residents worldwide
- 54,000 employees
- £8.4 billion turnover

Bupa has no
shareholders

Surplus
reinvested
creating a
broad-based
health and care
group

Bupa is run
entirely for
customers

Financial
success
supports
further
investment



Bupa Home Healthcare

- Established in 1975
- Provision of end-to-end out of hospital care
- More than 17,000 patients
- More than 13,000 deliveries to patients each month
- 3 aseptic compounding units
- 5 registered pharmacies
- Work with more than 200 NHS Hospital Trusts
- Approximately 600 nurses and care support workers



Our therapies



- Home assessment
- Discharge planning
- Aseptic manufacturing
- Dispensing
- Home delivery of drug & equipment
- Clinical waste collection
- Nursing support
- Patient services
- Compliance monitoring

Drug compounding, delivery and adherence programmes	Home Infusions	Complex and continuing care
Multiple Sclerosis treatments	Cystic Fibrosis therapy	Full spectrum of care from low to high dependency support
Growth Hormones	IV infection treatments	Flexible quality care at home, school/college or work
Rheumatoid Arthritis treatments	Oncology	24 hour nursing care
	Home Parenteral Nutrition	

Regulatory Assurance



Licensed and regularly inspected

- Medicines and Healthcare Products Regulatory Agency
- Care Quality Commission
- Social Care and Social Work Improvement Scotland
- General Pharmaceutical Council



Professional standards

- Essential Standards of Care
- General Medical Council
- Nursing and Midwifery Council
- Health Professionals Council
- Royal Pharmaceutical Society of Great Britain



Quality standards

- Accredited under ISO 9001-2008
- Contractors Health & Safety Assessment Scheme (CHAS)
- Connecting for Health (CfH) Information Governance Toolkit



Out of Hospital Care

Why move healthcare out of hospital?

Capacity and Resourcing

Freeing up bed space, pharmacy and nursing resource for a system currently struggling with a growing and ageing population

Financial efficiencies

Analysis indicates substantial cost benefits of moving care into the home environment to assist realising the required cost savings

Patient experience and choice

Evidence suggests patients would prefer to receive care, where appropriate, safe and clinically effective, in their own homes



“The service saves almost 4000 bed days a year and creates savings for the local health economy.”

Dr Paul Chadwick, Consultant
Microbiologist, Salford Royal NHS
Foundation Trust

'Taking the Pressure Off' : Demonstrating value to NHS

Opportunity to save a total of **14.5 million bed days** through early discharge and more care being delivered in the home. This equates to:

**£1.3 - £1.7bn
opportunity cost
reduction**



- The management of infections and reducing readmissions within the elderly population were identified as key areas
- Reduce avoidable hospital readmissions and increase capacity

Antibiotic resistance – Headlines

Antibiotics resistance 'as big a risk as terrorism' - medical chief

BBC News - 11 March 2013

Medical Officer: 'Now is the time' to act on antibiotics

ITV News – 11 March 2013

Antibiotic Resistance 'A Ticking Time Bomb'

Sky News – 11 March 2013

Resistance to antibiotics is 'ticking time bomb' - stark warning from Chief Medical Officer Dame Sally Davies

The Independent – 11 March 2013

Health chief warns on antibiotics threat

Financial Times – 11 March 2013

Antibiotics are 'ticking time-bomb', warns medical chief

The Telegraph – 11 March 2013

New wave of 'superbugs' poses dire threat, says chief medical officer

The Guardian – 11 March 2013

Trust Benefits

Our research shows that the cost of treating a patient at home on IV antibiotics is 47% of the equivalent in-patient cost.

EXAMPLE SAVINGS CALCULATION FOR OSETEOMYELITIS (TEICOPLANIN 600MG OD)

Pure cost saving

Estimate of current in-house costs (per day)	Bupa Home Healthcare charge (per day)	Saving per day	Bed days for 15 beds (365 days/year)	Saving
£300	£160	£140	5,475	£766,500

Additional income from beds


Estimate of income per day	Estimate of current in-house costs (per day)	Profit per bed day	Bed days for 15 beds (365 days/year)	Additional income	Total benefit
£350	£300	£50	5,475	£273,750	£1,040,250

Bupa Home Healthcare charge per day is an all inclusive indicative price including a registered nurse visit to the patients home to administer the drug.

Patients Benefits

Patients experience an improved quality of life by receiving treatment in the comfort of their own home:

- Hospital-acquired infection risk is reduced.
- Patients are able to continue with everyday activities with little disruption.
- Travel costs to hospital are reduced.
- Friends and family are not restricted by visiting hours.



Patient Benefits

In our experience, an OPAT service could include treatment of the following conditions:

Potential Conditions:

- Brain abscess
- Cellulitis
- Skin infection
- COPD
- Osteomyelitis
- Infective endocarditis
- Breast drain
- Bronchiectasis
- Urinary tract infection
- Liver abscess
- Discitis
- Dehydration
- Diabetic foot

“Our findings show that patients value our services highly, with 99% rating the overall Bupa Home Healthcare service as excellent or good”

Patient Satisfaction Survey 2010 - 2011




THE OPAT EXPERIENCE

The Service

- Our dedicated patient co-ordination team organise the patient transfer from hospital to home.
- Our fully trained local nurses are available to visit patients once or twice a day to administer the treatment.
- They can also train patients to administer their own treatment.
- Medication will be compounded in our in-house aseptic manufacturing units and delivered to the patient's home.
- Clinical waste is collected from the patient's home at the next scheduled delivery.



Patient Journey: Early Discharge



Case Study

The Salford Royal NHS Foundation Trust and Bupa Home Healthcare Home and Outpatient Intravenous Therapy Service (HOPT):

- The home IV service began as pilot in 2000, during which time the patient pathway and service model was developed.
- The HOPT scheme was then set up as an established service in 2003.
- The partnership ensures that all patients have access to the home IV service.
- We provide nursing support for patients who live outside the Salford area, while NHS district nurses manage the patients who live within the area.



- The HOPT scheme **saves Salford Royal NHS Foundation Trust more than 3500 bed days a year and releases 10 beds for additional activity.**
- **No patients contracted line infections** as a result of the high standards of care by trained community IV nurses.

Thank you. Any questions?

To find out more about our OPAT service, please call 0800 688 8685 or email:

opat@bupahomehealthcare.com

www.bupa.co.uk/opat



Medication and Stability

Drug	Approved Manufacturers	Vial Size	Device							
			Intermate		Eclipse		Syringe		Minibag	
			Conc range	Shelf life	Conc range	Shelf life	Conc range	Shelf life	Conc range	Shelf life
Ambisome	Gilead Sciences		N/A	N/A	N/A	N/A	N/A	N/A	0.5-2mg/ml	7d
Amikacin	BMS, Hospira	500mg/2ml	0.25-20mg/ml	30d	10-20mg/ml	29d	N/A	N/A	0.25-20mg/ml	30d
Aztreonam	ER Squibb	1g	5-60mg/ml	29d	5-60mg/ml	29d	1-200mg/ml	21d	5-60mg/ml	29d
		2g								
Ceftazidime	Genus, GSK, Flynn	1g	5-40mg/ml	10d	5-60mg/ml	14d	50-200mg/ml	7d	5-40mg/ml	14d
		2g								
		500mg								
Ceftriaxone	Roche	1g	5-40mg/ml	22d	20mg/ml	3d	100-250mg/ml	10d	40-100mg/ml	10d
		2g								
Ciprofloxacin	Bayer	200mg/100ml	0.5-2mg/ml	90g	2mg/ml	29d	N/A	N/A	0.5-2mg/ml	30d
		400mg/200ml								
Colistimethate Sodium (Colistin)	Forest Labs	1mu	12,500-37500iu	30d	20,000iu/ml	14d	200,000iu/ml	28d	12,500-62,500iu/ml	30d
		2mu								
Flucloxacillin	Wockhardt, GSK, Bowmed	1g	15-20mg/ml	21d	10-30mg/ml	15d	25.1-125mg/ml	14d	5-20mg/ml	14d
		500mg								
		250mg								
Gentamicin	SanofiAventis, Mayne/Hospira	80mg/2ml	0.5-5mg/ml	10d	N/A	N/A	10-40mg/ml	28d	1-5mg/ml	7d
Meropenem	Hospira, AztraZenica	1g	5-10mg/ml	3d	5-10mg/ml	3d	N/A	N/A	N/A	N/A
		500mg								
Piperacillin/Tazobactam (Tazocin)	Wyeth, Stragen	2.5g	11.25-90mg/ml	7d	11.25-90mg/ml	14d	168.75-225mg/ml	7d	11.25-90mg/ml	7d
		4.5g								
Teicoplanin	SanofiAventis		1.5-8mg/ml	28d	1-4mg/ml	29d	N/A	N/A	1.5-8mg/ml	28d
Temocillin	Eumedica		10-20mg/ml	21d	10-20mg/ml	21d	N/A	N/A	N/A	N/A
Timentin	GSK		10-150mg/ml	10d	N/A	N/A	N/A	N/A	32mg/ml	3d
Tobramycin	Mayne/Hospira, King, Medimpex	80mg/2ml	0.5-4.8mg/ml	10d	1-13.5mg/ml	21d	1-40mg/ml	28d	0.5-5mg/ml	9d
Vancomycin	Flynn, Mayne/Hospira	1g	1-10mg/ml	28d	5mg/ml	14d	10mg/ml	30d	1-10mg/ml	28d
		500ml								